1. Al-Mohammed HI, Chance ML, Bates PA. Production and characterization of stable amphotericin-resistant amastigotes and promastigotes of Leishmania mexicana. Antimicrob. Agents Chemother. 2005;49:3274-3280.

2. Anadón A, Martínez-Larrañaga MR. Fármacos Antiparasitarios. En: Velásquez Farmacología Básica y Clínica. P Lorenzo, A Moreno, JC Leza, I Lizaoain y Ma Moro, eds. 17ª Edición. Editorial Médica Panamericana. Buenos Aires. 2005. Cap. 53. pp.:881-905.

3. Bakker-Grunwald T. Ion transport in parasite protozoa. J. Exp. Biol. 1992; 172: 311-322.

4. Barret MP, Mottram JC, Coombs GH. Recent advances in identifying and validating drug targets in Trypanosomes and Leishmanias. Trends. Microbiol. 1999; 7 :82-88.

5. Basselin M, Robert-Gero M. Alterations in membrane fluidity, lipid metabolism, mitochondrial activity and lipophosphoglycan expression in pentamidine-resistant Leishmania. Parasitol. Res. 1998; 60:78-83.

6. Bates PA, Tetley L. Leishmania mexicana: induction of metacyclogenesis by cultivation of promastigotes at acidic pH. Exp. Parasitol. 1993;76:412-423.

7. Bates M, Wrin T, Huang W, y col. Practical applications of viral fitness in clinical practice. Curr. Opin. Infect. Dis. 2003;16:11-18.

8. Belkaid Y, Kamhawi S, Modo G, y col. Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long term outcome of Leishmania major infection in the mouse ear dermis, J. Exp. Med. 1998; 188:1941-1953.

9. Benaim G, Szabo V, Cornivelli L. Isolation and characterization of calmodulin from Leishmania braziliensis and Leishmania mexicana. Acta Cient. Venezol. 1987; 38: 289-291.

10. Benaim G, Cervino V, Salerno M, y col. Mecanismos de señalización, regulación iónica y resistencia a drogas en tripanosomátidios. Mem. IBE.1998;1:13-16.

11. Berberich C, Marín M, Ramírez JR, y col. The metacyclic stage-expressed Meta-1 gene is conserved between Old and New World Leishmania species. Mem. Inst. Oswaldo Cruz. 1998;93:819-821.

12. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis. 1997; 24:684-703.

13. Beverley SM, Coderre JA, Santi DV, y col. Unstable DNA amplification in methotrexate resistant Leishmania consists of extrachromosomal circles which relocalize during stabilization. 1984. Cell. 38:431-439.

14. Beverley SM. Genetic and genomic approaches to the analysis of Leishmania virulence. En: Molecular and Medical Parasitology. J Marr, T Nilsen, R Komunecki, eds. Academic Press, Elsevier, Amsterdam. 2001. Cap 6. pp.:111-123.

15. Borst P, Oullette M. New mechanism of drugs resistance in parasitic protozoa. Ann. Rev. Microbiol.1995;49:427-460.

16. Blum JL. Effect of osmolality on 86Rb⁺ uptake and release by Leishmania donovani. J. Cell. Physiol. 1992;152:111-117.

17. Blum J. Intermediary metabolism of Leishmania. Parasitol. Today 1993;9:118-122.

18. Blum J. Energy metabolism in Leishmania. J. Bioenerg. Biomemb. 1994;26:147-154

19. Bogdan C, Gessner A, Solbach W, y col. Invasion, control and persistence of Leishmania parasites. Curr. Op. Inmunol. 1996; 8: 517-525.

20. Bryceson ADM. Diffuse cutaneous leishmaniasis, the clinical and histopatological features of the disease in Ethiopia. Trans. R. Soc. Trop. Hyg Med. 1972;63:708-737.

21. Buates S, Matlashewski G. Treatment of experimental leishmaniasis with the inmunomodulators imiquimod. J. Infect. Dis. 1999; 179:1485-1494.

22. Cappai R, Morris L, Aebischer T, y col. Ricin-resistant mutants of Leishmania major which express modified lipophosphoglycan remains infective for mice. Parasitology. 1994;108:397-405.

23. Connor DH, Gibson DW. Enfermedades infecciosas y parasitarias. En: Patología-Fundamentos. E Rubin y JL Farber, eds. Editorial Médica Panamericana. México DF. 1992. Cap.9. pp.:210-213.

24. Consigli J, Danielo C, Gallerazo V, y col. Cutaneous leishmaniasis: successful treatment with itraconazole. Int. J. Dermatol. 2006; 45:46-49.

25. Convit J. The Kellersberger Memorial Lecture: leprosy and leishmaniasis similar clinical inmunological-pathological models. Ethiop. Med. J.1974; 12:187-95.

26. Convit J, Castellanos PL, Rondón A, y col. Inmunotherapy versus Chemotherapy in localised cutaneous leishmaniasis. Lancet. 1987; 8530:401-405.

27. Convit J, Ulrich M, Fernández CT, y col. The inmunological spectrum of American cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 1993; 87:444-448.

28. Convit J, Ulrich M, Polegre MA, y col. Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin: preliminary report. Mem. Inst. Oswaldo. Cruz. 2004;99:57-62.

29. Convit J, Ulrich M, Pérez M, y col. Atypical cutaneous leishmaniasis in Central America: possible interaction between infectious and environmental elements. Tran. R. Soc. Trop. Med. Hyg. 2005; 99:13-17.

30. Croft SL, Pendergast W, y col. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem. Pharmacol. 1987; 36:2633-2636.

31. Croft SL, Coombs GH. Leishmaniasis: Current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 2003; 19:502-508.

32. Croft SL, Sundar S, Fairlamb AH. Drug Resistance in Leihsmaniasis. Clin Microbiol. Rev. 2006; 19:111-126.

33. Curtis CF. Personal protection methods against vectors of disease. Rev. Med. Vet. 1992; 80:543-553.

34. Chang KP, Reed SG, McGwire BS, y col. Leishmania model for microbial virulence: the relevance of parasite multiplication and pathoantigenicity. Acta Trop. 2003; 85:375-390.

35. Chen GX, Meuller C, Wendlinger M, y col. Kinietic and molecular propierties of the dihydrofolate reductase from pyrimethamine-sensitive and pyrimethamine-resistant clones of the human malaria parasite Plasmodium falciparum. Mol. Pharmacol.1987;31:430-437.

36. Debrabant A, Nakhasi H. Programmed cell death in trypanosomatids: is it an altruistic mechanism for survival of the fittestá Kinetoplastid Biol. Dis. 2003;2:7.

37. Delgado O, Guevara P, Silva S, y col. Follow up of human accidental infection by Leishmania braziliensis using conventional inmunologic techniques and polymerase chain reaction. Am. J. Trop. Med. Hyg. 1996;51:267-272.

38. Detke S, Chaudhuri G, Kink JA, y col. DNA amplification in tunicamycin-resistant Leishmania mexicana: multicopies of a single 63-kilobase supercoiled molecule and their expression. J. Biol. Chem. 1988;263:3418-3424.

39. DiFranco M, Villaroel A, Ponte-Sucre A, y col. Incorporation of ion channels from the plasma membrane of L.mexicana into planar bilayers. Acta Cient. Venez. 1995; 46: 206-207.

40. Dos Reis G. Susceptible Hosts: a resort for parasites right in the eye of the immune response. An. Acad. Bras. Cienc. 2000;72:79-52.

41. Eibl H, Unger C. Hexadecylphosphocholine: a new and selective antitumor drug. Cancer. Treat. Rev. 1990; 17: 233-242.

42. Elhay M, Kelleher M, Bacic A, y col. Lipophosphoglycan expression and virulence in ricin-resistant variants of Leishmania major. Mol. Biochem. Parasitol. 1990;40:255-267

43. Ellenbeger TE, Beverly, SM. Multidrug resistance and conservative amplification of the H region in L. major. J. Biol. Chem.1989;264:15094-15103.

44. Escobar P, Yardley V, Croft SL. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob. Agents Chemother. 2001;45:1872-5.

45. Essodaigui M, Frezard F, Moreira ES, y col. Energy-dependent efflux from Leishmania promastigotes of substrates of the mammalian multidrug resistance pumps. Mol. Biochem. Parasitol. 1999;100:73-84.

46. Evans R, Albornoz R. Principios de Epidemiología Moderna. Editorial EBVC. Caracas, 2000; pp. 233-240.

47. Feliciangeli MD, Zerpa O, Rodríguez N, y col. Hallazgo de Lutzomyia longipalpis (Diptera Psychodidae) naturalmente infectada con promastigotes en un foco endémico de leishmaniasis visceral en la Isla de Margarita, Venezuela. Bol. Dir. Malariol. Saneam. Amb. 1998;38:73-75.

48. Feliciangeli MD, Rabinovich J. Abundance of Lutzomyia ovallesi but not Lu. gomezi (Diptera: Psychodidae) correlated with cutaneous leishmaniasis incidence in north-central Venezuela. Med. Vet. Entomol. 1998;12:121-131.

49. Figarella K, Uzcátegui N, García N, y col. Molecular pharmacology of chemo-resistant Leishmania. Archiv. Venezol. Farmacol. Terap. 2003; 22:19-24.

50. Finegold SM, Barón EJ. Diagnóstico microbiológico 7ª Ed. SM Finegold, EJ Barón eds. Editorial Médica Panamericana, Buenos Aires. 1992. Cap 10. pp.:151-162.

51. García N, Figarella K, Mendoza-León A, y col. Changes in the infectivity, pyruvate kinase activity, acid phosphatase activity and P-glycoprotein expresión in glibenclamide-resistance Leishmania mexicana. Parasitol. Res. 2000; 86: 899-904.

52. Gazola KC, Ferreira AV, Anacleto C, y col. Cell surface carbohydrates and in vivo infectivity of glucantime sensitive and resistant Leishmania (viannia) guyanensis cell lines. Parasitol. Res. 2001;87:935-940.

53. Guevara P, Pinto-Santini D, Dias M, y col. Desarrollo y aplicación de herramientas moleculares para el estudio de la biología parásito-vector en los sistemas: Leishmania-Phlebotomo y Tripanosoma cruzi y Tripanosoma rangeli-Triatomino. Mem. IBE. 2001; 3:137-140.

54. Heby O, Persson L, Rentala M. Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas' disease, and leishmaniasis. Amino Acids. 2007 33:359-66.

55. Hendrikson N, Sifiri CD, Henderson DM, y col. Molecular characterization of the ldmdr1 multidrug resistance gene from Leishmania donovani. Mol. Biochem. Parasitol. 1993;60:53-64.

56. Higgins CF. ABC transporters: from microorganisms to man. Ann. Rev. Cell. Biol. 1992;8:67-113.

57. Hirst, SI, Stapley, LA. Parasitology: the dawn of a new millennium. Parasitol. Today. 200;16: 1-3.

58. Ismael AY, Garmson JC, Molyneux DH, y col. Transformation development and transmission of axenically cultured amastigotes of L. mexicana in vitro and in Lutzomya longipalpis. Am. J.Trop. Med. Hyg. 1998;59:421-425.

59. Jiang S, Anderson SA, Winget GD, y col. Plasma membrane K⁺/H(+)-ATPase from Leishmania donovani. J. Cell. Physiol. 1994; 159:60-66.

60. Kink JA, Chang KP. Biological and biochemical characterization of tunicamycin-resistant Leishmania mexicana: mechanism of drug resistance and virulence. Infect. Immun. 1987;55:1692-1700.

61. Lainson R, Shaw JJ. Leishmaniasis of the New World: taxonomic problems. Br. Med. Bull. 1972; 28: 44-48.

62. Lerner EA, Ribeiro JM, Nelson RJ, y col. Isolation of maxadilan, a potent vasodilatadory peptide from the salivary glands of the sandfly Lutzomyia losgipalpis. J. Biol. Chem. 1991; 261: 11234-11236.

63. Liew FY, O?Donnel CA. Inmunology of leishmaniasis. Adv. Parasitol. 1993; 32: 1172-1259.

64. Locksley RM. Leishmaniasis. En: Harrinsonís Principles of Internal Medicine. 13° edition. DL Kasper, E Braunwald, A Fauci, SL Hauser, DL Longo, JL Jameson, eds. Mc Graw Hill. New York. 1994. Cap.175. pp.:897-899.

65. López-Jaramillo P, Ruano C Rivera J y col. Treatment of cutaneous leishmaniasis with nitric-oxid donor. Lancet. 1998;351:1176-1177.

66. Luis L, Ramírez A, Aguilar CM, et al. The genomic fingerprinting of the coding region of beta-tubulin gene in Leishmania identification. Acta Trop. 1998; 69: 193-204.

67. Machuca C, Rodríguez A, Herrera M, y col. Metabolic adaptations induced by resistance to glibenclamide in Leishmania amazonensis. Exp. Parasitol. 2006; 114.1-9.

68. Marchesini N, Docampo R. A plasma membrane P-type H atpase regulates intracellelar pH in Leishmania mexicana amazonensis. Mol. Biochem. Parasitol. 2002; 119:225-236.

69. Mbongo N, Loiseau PM, Billion MA, y col. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 1998;42:352-357.

70. Melby P. Recent developments in leishmaniasis. Curr. Opin. Infect. Dis. 2002; 15:485-490.

71. Mendoza-León A, Shau JJ, Tapia FJ. A guide for the Cutaneous Leishmaniasis Connoisseur. En: Molecular and inmune mechanisms in the pathogenesis of cutaneous leishmaniasis. FJ Tapía; G Cáceres-Dittmar and MA Sánchez, eds. RG.1996; Cap 1. pp.:1-23.

72. Ministerio de Salud y Desarrollo Social. Anuarios Epidemiológicos 1994-2002. Caracas. 2002.

73. Ministerio de Salud y Desarrollo Social. Departamento de Informática. Instituto de Biomedicina. Caracas. 2004

74. Molineux W, Killick-Kendrick R. Leishmaniasis in Biology and Medicine. En: Leishmaniasis in Biology and Medicine. W Peters y R Killick-Kendrick, eds. New York. Academic Press. 1987; cap 20. pp.:794-845.

75. Murray H. Clinical and experimental advances in treatment of Visceral Leishmaniasis. Antimicrob. Agents Chemother. 2001; 45:2185-2197.

76. Natera S, Machuca C, Padrón-Nieves M, y col. Proficiency of drug-resistant parasites. Int. J. Antimicrob. Agents. 2007; 29:637-42.

77. Neghme A, Llanos A, Naquira C. Leishmaniasis. En: Parasitología Médica. A Atías, ed. Publicaciones Técnica Mediterráneo. Chile;1999. Cap. 29. pp.:248-254.

78. Nourbakhsh F, Uliana SR, Smith DF. Characterisation and expression of a stage-regulated gene of Leishmania major. Mol. Biochem. Parasitol. 1996;76:201-213.

79. Organización Mundial de la Salud (OMS). Communicable disease surveillance and response. Leishmaniasis and Leishmania/HIV co-infection. 2001.

80. Organización Mundial de la Salud (OMS). Communicable disease. 2002; 104-150.

81. Organización Mundial de la Salud (OMS). Control de la leishmaniasis. Informe de la Secretaría 118º Reunión. 2006:1-7.

82. Ouellette M, Fase-Fowler F, Borst P. The amplified H circle of metothrexate-resistant Leishmania tarantolae contains a novel P-glycoprotein gene. EMBO J.1990;9:1027-1033.

83. Ouellette M, Drummelsmith J, Papadopoulou B. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug. Resist. Update. 2004; 7:257-66.

84. Overath P, Aerbischer T. Antigen presentation by macrophages arbouring intravesicular pathogens. Parasitol. Today. 1999; 15:325-331.

85. Pérez-Victoria FJ, Gamarro F, Oullette M, y col. Functional cloning of the miltefosine transport. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J. Biol. Chem. 2003;278:49965-49971.

86. Phillips MA, Stanley SL. Quimioterapia de infecciones por protozoos. En: Goodman & Gilman Las Bases Farmacológicas de la Terapéutica 11ª Edición. JG Hardman, LE Limbird, AG Gilman Eds. Mc Graw Hill México. 2006; Cap. 40. pp.: 1049-1071.

87. Plock A, Presber W. Application of flow cytometry and microscopical methods to caracterize the effect of herbal drugs on Leishmania sp. Exp. Parasitol. 2001;97:141-153.

88. Ponte-Sucre A, Campos Y, Vazquez J, y col. Sensitivity of Leishmania spp. to glibenclamide and 4-aminopyridine: a tool for the study of drug resistance development. Mem. Inst. Oswaldo Cruz. 1997;92:601-6.

89. Ponte-Sucre A, Campos Y, Fernandez M, y col. Leishmania sp.: growth and survival are impaired by ion channel blockers. Exp. Parasitol. 1998;88:11-19.

90. Ponte-Sucre A. Physiological consequences of drug resistance in Leishmania and their relevance for chemotherapy. Kinetoplastid Biol. Dis. 2003;28:2-14.

91. Ponte-Sucre A, Vicik R, Schultheis M, y col. Aziridine-2,3-dicarboxylates, peptidomimetic cysteine protease inhibitors with antileishmanial activity. Antimicrob. Agents Chemother. 2006 Jul;50(7):2439-47.

92. Ponte-Sucre A, Faber JH, Gulder T, y col. Activities of naphthylisoquinoline alkaloids and synthetic analogs against Leishmania major. Antimicrob. Agents Chemother. 2007 Jan;51(1):188-94.

93. Prasad V, Kumar SS, Dey C. Resistance to arsenite modulates levels of a-tubulin and sensitivity to paclitaxel in Leishmania donovani. Parasitol. Res. 2000;86:838-842.

94. Ramos H, Brajtburg J. Evaluación de la actividad antileishmania de micelas mixtas de anfotericina B. Mem. IBE. 2001;3:17-20.

95. Rascon A. Intervención de la fosfodiesterasas de nucleótidos cíclicos en mecanismos de señalización celular. Mem. IBE 1998;1:29-32.

96. Rascon A. Fosfodiesterasas de AMPc en parásitos de la familia Trypanosomatidae. Mem. IBE. 2001;3:37-40.

97. Ravel C, Dubessay P, Bastien P, y col. The complete chromosomal organization of the reference strain of Leishmania genome project, L.major:Friedlin. Parasitol. Today 1998;14:301-303.

98. Reyes Romero H, Navarro Rojas P, y col. Infecciones por parásitos en trabajadores de la salud: transmisión y control. Rev. Inst. Hig. ?Rafael Rangel?. 2004; 35: 32-45.

99. Reyes Romero H, Navarro Rojas P, Ruiz Montufar H, y col. Leishmaniasis Tegumentaria Americana. Informe Médico. 2006; 8: 339-350.

100. Ridley D. The pathogenesis of cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 1999; 73:156-160.

101. Roberts CW, McLeod R, Rice DW, y col. Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol. Biochem. Parasitol. 2003;126:129-142.

102. Rodríguez N, Guzman B, Rodas A, y col. Diagnosis of cutaneous leishmaniasis and species discrimination of parasites by PCR and hibridization. J. Clin. Microbiol. 1994;32:2246-2252.

103. Rodríguez N, Aguilar CM, Barrios MA, y col. Detection of Leishmania braziliensis in naturally infected individual sandflies by the polymerase chain reaction. Trans. R. Soc. Trop. Med. Hyg. 1999;93:47-49.

104. Rodríguez N, Cardona M, Zerpa O, Barrios M, y col. Aplicación de herramientas moleculares en el diagnóstico y caracterización de Leishmania spp. En áreas endémicas de Venezuela. Bol. Malariol. Saneam. Amb. 2001;XLI:21-26.

105. Rodríguez N, De Lima H, Aguilar CM, y col. Molecular epidemiology of cutaneous leishmaniasis in Venezuela. Trans. R. Soc. Trop. Med. Hyg. 2002a;96:S1/105-S1/109.

106. Rodríguez N, Docampo R, Lu Hg HG, Scout DA. Overexpression of the Leishmania amazonensis Ca2+-ATPase gene lmaa1 enhances virulence. Cell. Microbiol. 2002b;4:117-26.

107. Rodríguez N, Bailey BN, Martin MB, y col. Radical cure of experimental cutaneous leishmaniasis by biphosphate pamidronate. J. Infect. Dis. 2002c;186:138-140.

108. Rodríguez N, De Guglielmo Z, Marrios MA, y col. Genetic homogeneity within Leishmania (L.) infantum isolated from human and dogs: the relationship with the sandfly fauna distribution in endemic areas of Nueva Esparta State, Venezuela. Parasitology. 2005; 130;611-619.

109. Rosenthal PJ, Goldsmith RS. Fármacos antiprotozoarios. En Farmacología Básica y Clínica8ª Edición. BG Katzung, ed. Editorial Manual Moderno. México. 2001; Cap 53. pp.:1007-1012.

110. Sandoval W, López C, Chiurillo M, y col. Análisis bioquímico y genético de las enzimas piruvato quinasa y fosfofructoquinasa de Leishmania. Mem. IBE 1998; 1:121-124.

111. Sereno F, Lemesre FJ. In vitro life cycle of pentamidine-resistant amastigotes: Stability of the chemoresistant phenotypes is dependent on the level of resistance induced. Antimicrob. Agents Chemother. 1997a;41:1898-1903.

112. Sereno D, Michon P, Brajon N, y col. Phenotypic characterization of Leishmania mexicana pentamidine-resistant promastigotes. Modulation of the resistance during in-vitro developmental life cycle. C. R. Acad. Sci. Ser III Sci. Vie. 1997b;320:981-987.

113. Serrano-Martín X, González-Luna D, Fuentes J, et al. Evaluación de drogas en Leishmania sp.: Estudios genéticos y moleculares de nuevos blancos. Estudios in vitro e in vivo de la resistencia a drogas. Mem.IBE. 2005; 4:117-120.

114. Silva N, Ponte-Sucre A. ABC proteins in Leishmania mexicana: modulation of parasite-host cell interaction. Arch. Venezol. Farmacol. Terap. 2001;21:134-138

115. Silva N, Camacho N, Figarella K, y col. Cell differentiation and infectivity of Leishmania mexicana are inhibited in a strain resistant to an ABC-transporter blocker. Parasitology. 2004;28:629-34.

116. Singh AK, Lee ST. Status of respiration and ATP content in arsenite resistant Leishmania mexicana amazonensis. Microb. Pathog. 1999;26:171-174.

117. Solbach W, Laskay T. The host response to Leishmania infection. Adv. Immunol. 2000;74: 275.

118. Soto J, Arana BA, Toledo J, y col. Miltefosine for New World cutaneous leishmaniasis. Clin. Infect. Dis. 2004; 38:1266-1272.

119. Suffia I, Schmid-Antomarchi H, Kubar J. 86 Rb+ transport in Leishmania infantum promastigotes under various in vitro culture conditions. Int. J. Parasitol. 1997;27:1547-1553.

120. Sundar S, Reed SG, Sharma S, y col. Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am. J. Trop. Med. Hyg. 1997; 56:522-525.

121. Thakur CP. Leishmaniasis research- the challenges ahead. Indian J. Med. Res. 2006;123:193-194.

122. Tracy JW, Webster LT. Fármacos en la quimioterapia de infecciones causadas por protozoarios. En: Goodman & Gilman Las Bases Farmacológicas de la Terapéutica 10ª Edición. JG Hardman, LE Limbird, AG Gilman Eds. Mc Graw Hill México. 2003; Cap. 41. pp.:1116-1136.

123. Ulrich M. Epidemiología y diagnóstico de la leishmaniasis. Ponencia en el Curso Latinoamericano del Instituto de Biomedicina. Caracas. 2004.

124. Urbina J. Intermediary metabolism of Trypanosoma cruzi. Parasitol. Today 1994; 10:107-110.

125. Urbina JA. Mechanisms of action of lysophospholipid analogues against trypanosomatid parasites. Trans. R. Soc. Trop. Med. Hyg. 2006;1001:S9-S16

126. Uzcategui NL, Figarella K, Camacho N, y col. Substrate preferences and glucose uptake in glibenclamide-resistant Leishmania parasites. Comp. Biochem. Physiol. C. Toxicol. Pharmacol. 2005;40:395-402.

127. Valdivieso E, Dagger F, Rascón A. Identificación y caracterización bioquímica de una aspartil-proteinasa presente en promastigotes de Leishmania mexicana. Mem. IBE. 2001;3:17-20.

128. Vercesi AE, Macedo DV, Lima SA, y col. Ca²⁺ transport in digitonin-permeabilized trypanosomatids. Mol. Biochem. Parasitol. 1990; 42: 119-124.

129. Vieira LL, Cabantchik ZI. Amino acid uptake and intracellular accumulation in Leishmania major promastigotes are largely determined by an H(+)-pump generated membrane potential. Mol. Biochem. Parasitol. 1995; 75:15-23.

130. Yardley V, Khan AA, Martin MB, y col. In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii. Antimicrob. Agents Chemother. 2002;46:929-31.

131. Zakai HA, Chance ML, Bates PA. In vitro stimulation of metacyclogenesis in Leishmania braziliensis, L. donovani, L. major and L. mexicana. Parasitology 1997;116:305-309.

132. Zerpa O, Ulrich M, Convit J. Programa Control de la Leishmaniasis Visceral en Venezuela. Publicación del Ministerio de Salud y Desarrollo Social, Universidad Central de Venezuela e Instituto de Biomedicina. 2003; pp. 8 -17.

133. Zerpa O. Terapia de leishmaniasis. Ponencia en el 1º Congreso Internacional de Terapéutica. Caracas. 2005.

134. Zilberstein D, Dwyer DM. Protonmotive force-driven active transport of D-glucose and L-proline in the protozoan parasite Leishmania donovani. Proc. Natl. Acad. Sci. U S A. 1985 Mar;82(6):1716-20.

135. Zilberstein D, Shapira M. The role of pH and temperature in the development of Leishmania parasites. Ann. Rev. Microbiol. 1994; 48:449-470.